Anti-Phospholipid Antibodies, Anticardiolipin Antibodies, Antiphospholipid Antibodies, Cardiolipin, Cardiolipin Antibodies, Antiphospholipid syndrome, APS, anti-B2-GP1 antibodies, Beta 2 glycoprotein, Beta-2 glycoprotein, Beta-2 GP1, systemic lupus erythematosus, SLE
This semi-quantitative test panel detects IgA, IgG and IgM antibodies to Cardiolipin and Beta-2 Glycoprotein to aid in the diagnosis of primary Antiphospholipid Syndrome (APS) and those secondary to systemic lupus erythematosus (SLE) or SLE-disorders.
The APLSAB test utilizes multiplex flow immunoassay, a methodology that greatly resembles traditional EIA, but permits simultaneous detection and identification of many antibodies in a single tube.
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the venous and/or arterial thrombosis, thrombocytopenia, recurrent fetal loss, and moderate-to-high titers of antiphospholipid (aPL) antibodies, lupus anticoagulant (LA), anti-Cardiolipin (aCL) antibodies, and anti-B2-GP1 antibodies. A definitive diagnosis of APS requires the presence of at least one clinical manifestation and on positive laboratory result. Due to the heterogeneous nature of aPL antibodies, combined measurements of ACL and B2GP1 antibodies may provide better sensitivity than either assay alone.
ACL IgA APL U/mL, ACL IgG GPL U/mL, ACL IgM MPL U/mL:
Beta 2 Glycoprotein IgA U/mL, Beta 2 Glycoprotein IgG U/mL, Beta 2 Glycoprotein IgM U/mL: